CoChat

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

Kudo, Masatoshi, Matilla, Ana, Santoro, Armando, Melero, Ignacio, Gracian, Antonio Cubillo, Acosta-Rivera, Mirelis, Choo, Su Pin, El-Khoueiry, Anthony B., Kuromatsu, Ryoko, El-Rayes, Bassel F., Numata, Kazushi, Itoh, Yoshito, Di Costanzo, Francesco, Crysler, Oxana V., Reig, Maria, Shen, Yun, Neely, Jaclyn, Dela Cruz, Christine Marie, Baccan, Carlos, Sangro, Bruno · 2019 · Journal of Clinical Oncology
Cited by 99

The DOI matches its Crossref record.

Abstract

327 Background: Pts with aHCC and CPB liver status are often excluded from clinical trials of novel therapies due to their poor prognosis (Greten British J Cancer 2005). Historical overall survival (OS) for these pts when treated with sorafenib (SOR) has ranged ≈3–5 mo in retrospective or descriptive studies (Abou-Alfa Gastrointest Cancer Res 2011; Da Fonseca Mol Clin Oncol 2015; Pressiani Ann Oncol 2013; Chiu Cancer 2012); thus, novel treatment options are needed for these pts. The PD-1 inhibitor NIVO is approved in the US, Canada, and elsewhere, most recently Australia, for SOR-treated pts with aHCC based on results from CheckMate-040 (NCT01658878) (El-Khoueiry Lancet 2017). Here we report data from the CPB cohort of CheckMate-040, the first prospective study of immunotherapy in this pt group. Methods: Pts with CPB (B7–B8) aHCC who were SOR-naïve (n = 25) or -experienced (n = 24) received NIVO 240 mg IV for 30 min Q2W until unacceptable toxicity or disease progression. Primary endpoints were objective response rate (ORR) (investigator assessed [INV], RECIST v1.1) and duration of response (DOR). Safety was assessed in all treated pts using NCI CTCAE v4.0. Results: Of 49 analyzed pts, 28 (57.1%) had vascular invasion or extrahepatic spread. During a follow-up range of 6–18 mo, INV ORR was 10.2% with 5 pts responding; disease control rate (DCR) was 55.1%. Median (m) time to response was 2.7 mo and mDOR was 9.9 mo; 2 pts had ongoing responses at data cutoff. The mOS was 7.6 mo (mOS follow-up was 7.4 mo); mOS in SOR-naïve and -treated pts was 9.8 and 7.3 mo, respectively. Treatment-related adverse events (TRAEs) were reported in 25 (51%) pts; 4 (8.2%) pts had select hepatic TRAEs. TRAEs led to discontinuation in 2 pts (4.1%). NIVO safety profile in these pts appeared comparable to cohorts of pts with CPA aHCC. Comparison data for pts with CPA aHCC and extended follow-up for pts with CPB aHCC will be presented. Conclusions: Encouraging DCR and durable responses were observed in pts with CPB aHCC treated with NIVO. AEs were manageable and did not lead to higher discontinuation compared with pts with CPA aHCC. NIVO showed promising efficacy and tolerability compared with historical data, supporting further investigation. Clinical trial information: NCT01658878.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2019.37.4_suppl.327

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 99

Metadata

Authors
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracian, A. C., Acosta-Rivera, M., Choo, S. P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B. F., Numata, K., Itoh, Y., Di Costanzo, F., Crysler, O. V., Reig, M., Shen, Y., Neely, J., Dela Cruz, C. M., Baccan, C., & Sangro, B.
Venue
Journal of Clinical Oncology
Published
2019-02-01
Volume
37
Issue
4_suppl
Pages
327-327
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2912094423
Cited by
99
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. https://app.cochat.ai/papers/10.1200/jco.2019.37.4_suppl.327
The paper
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracian, A. C., Acosta-Rivera, M., Choo, S. P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B. F., Numata, K., Itoh, Y., Di Costanzo, F., Crysler, O. V., Reig, M., Shen, Y., Neely, J., Dela Cruz, C. M., Baccan, C., & Sangro, B. (2019). Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2019.37.4_suppl.327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.